Treatment and prevention of alloreactivity using virus-specific immune cells expressing chimeric antigen receptors

Use of a virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR in the manufacture of a medicament for use in treating or preventing a disease or condition characterised by an alloreactive immune response, wherein the CAR comprises:

• (i) an antigen-binding domain which binds specifically to CD30, (i) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises:
• (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

A method of treating or preventing a disease or condition characterised by an alloreactive immune response, comprising administering to a subject a therapeutically or prophylactically effective quantity of virus-specific immune cells comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises:

• (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises:
• (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

A virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR for use in a method of treating or preventing a disease or condition by allotransplantation, wherein the CAR comprises:

• (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises:
• (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptortyrosine-based activation motif (ITAM).

Use of a virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR in the manufacture of a medicament for use in treating or preventing a disease or condition by allotransplantation, wherein the CAR comprises:

• (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises:
• (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

A method of treating or preventing a disease or condition by allotransplantation, comprising administering to a subject a therapeutically or prophylactically effective quantity of virus-specific immune cells comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises:

• (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (ii) a signalling domain, wherein the signalling domain comprises:
• (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptortyrosine-based activation motif (ITAM).

A method of killing alloreactive immune cells, comprising contacting alloreactive immune cells with a virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR for use in a method of treating or preventing a disease or condition characterised by an alloreactive immune response, wherein the CAR comprises:

• (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises:
• (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).